Suchen und Finden
Front Cover
1
Clinical and Translational Science
4
Copyright Page
5
Contents
8
List of contributors
10
Foreword
14
Acknowledgments
16
Introduction to Clinical Research
18
HISTORICAL BACKGROUND
18
ORGANIZATION OF THIS BOOK
20
REFERENCES
21
Part I: Fundamental Principles
22
Chapter 1 Patient-Oriented Research: Clinical Pathophysiology and Clinical Therapeutics
24
INTRODUCTION
24
TYPES OF PATIENT-ORIENTED RESEARCH
24
THE ROLE OF PATIENT-ORIENTED RESEARCH IN TRANSLATIONAL RESEARCH
27
SEQUENCE OF INVESTIGATION
27
CONCLUSIONS
31
REFERENCES
32
Chapter 2 Clinical Trials
34
INTRODUCTION
34
HISTORY
34
PHASES OF EVALUATION OF THERAPIES
34
CRITICAL GENERAL CONCEPTS
35
EXPRESSING CLINICAL TRIAL RESULTS
36
CONCEPTS UNDERLYING TRIAL DESIGN
38
GENERAL DESIGN CONSIDERATIONS
41
LEGAL AND ETHICAL ISSUES
43
HYPOTHESIS FORMULATION
47
PUBLICATION BIAS
48
STATISTICAL CONSIDERATIONS
48
META-ANALYSIS AND SYSTEMATIC OVERVIEWS
49
UNDERSTANDING COVARIATES AND SUBGROUPS
50
THERAPEUTIC TRUISMS
51
STUDY ORGANIZATION
51
INTEGRATION INTO PRACTICE
54
THE FUTURE
55
ACKNOWLEDGMENT
55
REFERENCES
56
Part II: Approaches
60
Chapter 3 Experimental Design
62
INTRODUCTION
62
HYPOTHESIS DEVELOPMENT
62
STUDY DESIGN OPTIONS
63
CONTROL OF BIAS
64
SAMPLE SIZE
66
ENDPOINTS
68
DATA MANAGEMENT
71
STATISTICAL ANALYSIS
75
CONCLUSION
77
REFERENCES
77
Chapter 4 Introduction to Biostatistics Ideas
80
BIOSTATISTICS: WHAT IS IT?
80
EVIDENCE: HOW MANY HEADS ON THIS COIN?
80
POPULATIONS AND DISTRIBUTIONS
81
SAMPLES
81
CLINICAL MEASURES OF INTEREST: WHAT DO WE WANT TO KNOW?
81
DATA AS SAMPLES: DISPLAY, LOOK AND THINK
83
THE MOST IMPORTANT PROBABILITY MODEL IN MEDICINE
83
THE CIRCLE OF INFERENCE
85
CENTRAL LIMIT THEOREM (CLT)
85
ESTIMATING THE TRUE POPULATION VALUE
86
TESTING PRE-SPECIFIED HYPOTHESES
87
THE MIGHTY P
87
REGRESSION ANALYSIS
88
THE MAIN POINTS ONCE AGAIN
88
REFERENCES
89
Chapter 5 Measurement of Biological Materials
90
INTRODUCTION
90
IMMUNOASSAYS AND IMMUNOCHEMISTRY
90
RADIOIMMUNOASSAYS
91
CHROMATOGRAPHY
93
MASS SPECTROMETRY (MS)
96
GENOMICS (GENE EXPRESSION MICROARRAYS)
99
PROTEOMICS
101
METABOLOMICS
103
REFERENCES
106
Chapter 6 Imaging Tools in Human Research
108
INTRODUCTION
108
IMAGING TECHNOLOGIES: A BRIEF OVERVIEW
108
IMAGING TECHNOLOGIES: HUMANS AND SMALL ANIMALS
111
SUMMARY
123
ACKNOWLEDGMENTS
123
REFERENCE
123
Chapter 7 Imaging Tools in Cardiovascular Research
126
INTRODUCTION
126
IMAGING AND RISK STRATIFICATION
126
PRESSURE WAVEFORM ANALYSIS AND ARTERIAL STIFFNESS
129
ARTERIAL IMAGING
135
ULTRASOUND IMAGING OF THE HEART
138
SUMMARY
139
REFERENCES
141
Chapter 8 Nanotechnology in Clinical and Translational Research
144
INTRODUCTION AND HISTORICAL PERSPECTIVE
144
NANOTECHNOLOGY IN BASIC RESEARCH APPLICATIONS SUPPORTING CLINICAL TRANSLATION
145
CLINICAL APPLICATIONS OF NANOTECHNOLOGY FOR RESEARCH
145
CONCLUSION AND FUTURE DIRECTIONS IN NANOMEDICINE
154
REFERENCES
154
Chapter 9 The Use of Questionnaires and Surveys
158
INTRODUCTION
158
THE PRACTICE OF QUESTIONNAIRE AND SURVEY MEASUREMENT
158
REFERENCES
173
Chapter 10 Information Technology
176
INTRODUCTION
176
CLINICAL DATA REPOSITORIES (CDRs)
176
PRINCIPLES OF DATA WAREHOUSING
177
INFORMATION TECHNOLOGY SUPPORT OF PARTICIPANT RECRUITMENT
182
PRINCIPLES OF DATA COLLECTION
183
DATA STANDARDS
184
CLINICAL TRIAL MANAGEMENT SYSTEMS
185
PUBLICLY AVAILABLE DATABASES
186
THE GROWING IMPACT OF THE WEB
187
SUMMARY
187
REFERENCES
187
Part III: Infrastructure
190
Chapter 11 Clinical and Translational Science Infrastructure
192
INTRODUCTION
192
BACKGROUND
192
REINVENTING THE CLINICAL RESEARCH INFRASTRUCTURE
193
CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTES
194
STRUCTURAL COMPONENTS OF A CLINICAL AND TRANSLATIONAL SCIENCE AWARD
195
CTSA SCIENTIFIC REVIEW
198
COLLECTIVE INITIATIVES OF THE CTSA CONSORTIUM
200
CONCLUSION
201
REFERENCES
202
Chapter 12 Industry-Sponsored Clinical Research in Academia
204
INTRODUCTION
204
THE PUBLIC PERSPECTIVE
204
THE AHC PERSPECTIVE
205
THE INDUSTRY PERSPECTIVE
205
THE INVESTIGATORS’ PERSPECTIVE
206
MATCHING INDUSTRY NEEDS AND AHC INTERESTS
206
ACADEMIC CLINICAL TRIALS CENTERS AS A SOLUTION
207
FINANCING CTCs
207
IT SOLUTIONS TO IMPROVE PATIENT ENROLLMENT
208
CONCLUDING REMARKS
208
ACKNOWLEDGMENT
209
REFERENCES
209
Part IV: Education, Training and Career Choices
210
Chapter 13 Training Basic, Clinical and Translational Investigators
212
INTRODUCTION
212
OVERVIEW
212
DIDACTIC CURRICULUM
213
DEGREE-GRANTING PROGRAMS IN CLINICAL OR TRANSLATIONAL RESEARCH
218
THE MENTORED RESEARCH EXPERIENCE
219
CAREER DEVELOPMENT RESOURCES
219
FUNDING FOR TRAINING CLINICAL AND TRANSLATIONAL INVESTIGATORS
219
REFERENCES
220
Chapter 14 A Stepwise Approach to a Career in Translational Research
222
DEFINITIONAL ISSUES
222
HISTORICAL PERSPECTIVE
222
STEP 1: THE STARTING POINT
223
STEP 2: THE NEED FOR NORMATIVE DATA AND CONTROL POPULATIONS
224
STEP 3: ENGAGEMENT OF RELEVANT BASIC RESEARCHERS AND TECHNOLOGIES
224
STEP 4: IDENTIFYING TRACTABLE PROBLEMS
224
STEP 5: IDENTIFYING APPROPRIATE MENTORS ACROSS A CAREER
225
STEP 6: OBTAINING SUCCESSFUL INDEPENDENT FUNDING
225
STEP 7: THE PERILS OF SENIOR LEADERSHIP
226
SUMMARY
226
REFERENCES
226
Chapter 15 Physician Careers in Industry
228
INTRODUCTION
228
PHASE 1 STUDIES
228
PHASE 2 STUDIES
229
PHASE 3 STUDIES
229
PHASE 4 STUDIES
229
CAREERS IN THE PHARMACEUTICAL INDUSTRY
229
CONCLUSION
236
REFERENCES
236
Part V: Funding
238
Chapter 16 Governmental Support of Research
240
OVERVIEW
240
INTRODUCTION
240
UNITED STATES GOVERNMENT SCIENTIFIC PROGRAMS IN 2007
240
SCIENTIFIC PROGRAMS IN EUROPE, CANADA AND AUSTRALIA/NEW ZEALAND
247
SCIENTIFIC PROGRAMS IN ASIA, AFRICA AND SOUTH/CENTRAL AMERICA AND THE CARIBBEAN
249
CURRENT SUPPORT FOR CLINICAL AND TRANSLATIONAL RESEARCH
253
PUTTING GOVERNMENT HEALTH RESEARCH INTO PERSPECTIVE
254
ACKNOWLEDGMENT
254
BIBLIOGRAPHY
255
REFERENCES
256
Chapter 17 Support of Health Research by Private Philanthropy
258
OVERVIEW
258
INTRODUCTION: GROWTH IN AMERICAN PHILANTHROPY AND ITS ROLE IN SUPPORTING MEDICAL RESEARCH
258
TYPES OF NONPROFIT, NONGOVERNMENTAL FUNDING FOR MEDICAL RESEARCH
260
FUNDING ALONG THE CONTINUUM OF BIOMEDICAL AND HEALTH RESEARCH
264
FOUNDATION FUNDING STRATEGIES – ‘HOW’ TO FUND
270
APPROACHING FOUNDATIONS
271
SUMMARY
273
ACKNOWLEDGMENTS
274
REFERENCES
274
Chapter 18 Pharmaceutical and Biotechnology Sector Support of Research
276
INTRODUCTION
276
THE DRUG DEVELOPMENT PROCESS
276
BASIC SCIENCE WITHIN THE PHARMACEUTICAL AND BIOTECHNOLOGY SECTORS
277
DEVELOPMENTAL RESEARCH – A CONTRAST TO ACADEMIA AND GOVERNMENT
278
CLINICAL RESEARCH AND DEVELOPMENT
279
MARKETED PRODUCT RESEARCH
281
SUMMARY
281
FURTHER READING
282
Part VI: Human Genetics
284
Chapter 19 Introduction to Human Genetics
286
INTRODUCTION
286
BASIC MOLECULAR GENETICS
286
DNA STRUCTURE
286
DNA REPLICATION
287
TRANSCRIPTION
287
TRANSLATION
288
CHROMOSOME STRUCTURE AND FUNCTION
289
MITOSIS AND MEIOSIS
290
PATTERNS OF GENETIC TRANSMISSION
291
SINGLE GENE INHERITANCE (MENDELIAN INHERITANCE)
291
NONMEDELIAN INHERITANCE
292
MULTIFACTORIAL INHERITANCE (POLYGENIC INHERITANCE)
295
CYTOGENETICS AND CHROMOSOMAL DISORDERS
296
THE HUMAN GENOME
297
STRUCTURE AND ORGANIZATION OF THE GENOME
297
GENETIC VARIATION
298
MEDICAL APPLICATIONS
301
MOLECULAR DIAGNOSTIC TESTING
301
THERAPY OF GENETIC DISEASE
302
GENETIC COUNSELING
305
PHENOTYPING AND CLINICAL RESEARCH
307
THE PHENOTYPIC CHALLENGE
307
GENOTYPE–ENVIRONMENT INTERACTION
307
PHENOTYPIC COMPLEXITY
307
REFERENCES
308
BIBLOGRAPHY
308
Chapter 20 Epidemiologic and Population Genetic Studies
310
INTRODUCTION
310
DESIGN ISSUES IN GENETIC ASSOCIATION STUDIES
310
INTERPRETING RESULTS OF GENETIC ASSOCIATION STUDIES
314
FUTURE DIRECTIONS
318
REFERENCES
319
Chapter 21 Pharmacogenetics of Drug Metabolism
322
INTRODUCTION
322
PHARMACOGENETICS OF DRUG METABOLISM: HISTORICAL ASPECTS
323
GENETIC POLYMORPHISMS OF INDIVIDUAL DRUG METABOLIZING GENES
324
UGT
335
CONCLUSIONS
337
REFERENCES
337
Part VII: Human Pharmacology
340
Chapter 22 Introduction to Clinical Pharmacology
342
OVERVIEW
342
INTRODUCTION: MECHANISMS OF DRUG DISPOSITION AND INTERACTIONS
342
PRINCIPLES OF PHARMACOKINETICS
349
CONCLUSION
356
REFERENCES
356
Chapter 23 Toxicology and Genetics of Adverse Drug Events
360
THE MULTIFACTORIAL NATURE OF ADVERSE DRUG EVENTS
360
TYPES OF ADVERSE DRUG EVENTS
361
GENETICS TO GENOMICS
364
REFERENCES
364
Chapter 24 Good Clinical Practice and Good Laboratory Practice
366
OVERVIEW
366
GOOD CLINICAL PRACTICE
366
DEFINITION
366
RULES AND REGULATIONS
368
CLINICAL PRACTICE AND RESEARCH
369
KEY PARTICIPANTS IN CLINICAL RESEARCH
370
DOCUMENTATION AND RECORD KEEPING
374
DATA MANAGEMENT AND PRESENTATION
375
MONITORING AND COMPLIANCE
375
CONCLUSION
376
GOOD LABORATORY PRACTICE
376
DEFINITION AND SCOPE
376
ORGANIZATION AND PERSONNEL
377
MANAGEMENT OF THE TESTING FACILITY
377
TEST, REFERENCE AND CONTROL ARTICLES
378
PROTOCOL FOR AND CONDUCT OF A NONCLINICAL LABORATORY STUDY
379
RECORD KEEPING
379
REPORTING OF NONCLINICAL LABORATORY STUDY RESULTS
379
DISQUALIFICATION OF LABORATORY FACILITY RESOURCES
379
CONCLUSION
380
REFERENCES
380
Chapter 25 Modern Drug Discovery and Development
382
BACKGROUND: THE IRONY OF INNOVATION
382
DRUG DISCOVERY THROUGH THE TWENTIETH CENTURY
382
DRUG DISCOVERY IN THE TWENTY-FIRST CENTURY
384
PRECLINICAL DEVELOPMENT
387
CLINICAL DEVELOPMENT
389
NEW DRUG DEVELOPMENT PARADIGMS
396
REFERENCES
398
Part VIII: Societal Context of Human Research
402
Chapter 26 Translating Science to the Bedside: The Innovation Pipeline
404
REALITIES OF THE MARKETPLACE
404
IDEAS AND INNOVATIONS
407
WORKING WITH INDUSTRY
409
ENTREPRENEURSHIP
412
CLINICAL EVALUATION OF INNOVATIVE PRODUCTS
414
CONFLICTS OF INTEREST
417
SUMMARY
419
NOTES
419
BIBLIOGRAPHY
420
Chapter 27 Regulatory Environment
422
INTRODUCTION
422
THE US FOOD AND DRUG ADMINISTRATION
422
THE INVESTIGATIONAL NEW DRUG (IND) APPLICATION
425
OTHER REGULATORY AGENCIES
434
CONCLUSIONS
434
ACKNOWLEDGMENTS
435
BIBLIOGRAPHY
435
REFERENCES
435
Chapter 28 Ethical Issues in Translational Research and Clinical Investigation
436
INTRODUCTION
436
RESPONSIBILITY IN SCIENCE AND SOCIETY
437
ETHICS AND TRANSLATIONAL RESEARCH
437
GUIDING PRINCIPLES FOR THE RESPONSIBLE TRANSLATIONAL INVESTIGATOR
439
BEYOND ETHICS: REGULATIONS, COMPLIANCE AND PROFESSIONALISM IN TRANSLATIONAL RESEARCH
440
JUSTICE, BENEFICENCE AND RESPECT FOR PERSONS: FROM PRINCIPLES TO PRACTICE
441
REGULATION OF RESEARCH AND PROTECTION OF SUBJECTS
442
INDIVIDUALS AND THE CLINICAL RESEARCH PROCESS
447
PROFESSIONALISM IN CLINICAL RESEARCH
448
REFERENCES
448
Chapter 29 Clinical Research in the Public Eye
450
INTRODUCTION
450
THE CULTURAL CONTEXT OF RESEARCH
451
SCIENCE AND POLITICS
455
PUBLIC–PRIVATE COLLABORATION
457
CONCLUSION
458
ACKNOWLEDGMENTS
459
REFERENCES
459
Part IX: Research in Special Populations
462
Chapter 30 Acute Illnesses, Critical Care, Emergency and Surgical Patients
464
INTRODUCTION
464
TRIAL DESIGN
464
USUAL CARE IN CRITICALLY ILL PATIENTS
467
INFORMED CONSENT
469
OUTCOMES
473
ADVERSE EVENTS
476
CONCLUSION
478
REFERENCES
478
Chapter 31 Psychiatric Disorders
482
INTRODUCTION
482
DIAGNOSTIC ISSUES
482
TYPES OF STUDIES
483
TOOLS
485
STATISTICAL AND DESIGN ISSUES
489
SPECIAL ISSUES
490
A PRACTICAL SCHEMATIC APPROACH
493
REFERENCES
495
Chapter 32 Geriatrics
498
INTRODUCTION
498
WHAT IS DIFFERENT ABOUT AGING RESEARCH?
498
HOW AN AGING PERSPECTIVE AFFECTS RESEARCH TOPICS AND APPROACHES
502
THE EFFECT OF AGING ON THE PRAGMATICS OF RESEARCH
507
CONCLUSIONS AND RECOMMENDATIONS
513
REFERENCES
513
Chapter 33 Pediatrics
518
INTRODUCTION
518
WHAT IS DIFFERENT ABOUT PEDIATRIC RESEARCH?
518
ORPHAN (RARE) DISEASES
520
PEDIATRIC CONDITIONS AS FOCUS OF INQUIRY
523
REGULATORY AND ETHICAL ENVIRONMENT FOR PEDIATRIC RESEARCH
524
CONCLUSION
525
REFERENCES
526
Part X: Population-Based Research
530
Chapter 34 Pharmacoeconomics: The Economic Evaluation of New Medical Technology
532
INTRODUCTION
532
THE EVALUATION OF NEW MEDICAL TECHNOLOGY: THE PRODUCER’S PERSPECTIVE
532
THE EVALUATION OF NEW MEDICAL TECHNOLOGY: THE END USER’S PERSPECTIVE
534
THE EVALUATION OF NEW MEDICAL TECHNOLOGY: SOCIETY’S PERSPECTIVE
536
COST–BENEFIT, COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS
538
CAN ONE EVER AVOID PUTTING MONETARY VALUES ON HEALTH BENEFITS?
543
UNRESOLVED CONTROVERSIES ON ECONOMIC VALUATIONS IN HEALTHCARE
545
NOTES
546
REFERENCES
546
Chapter 35 Introduction to Epidemiology
548
INTRODUCTION
548
DEFINITION AND ROLE OF EPIDEMIOLOGY
548
MEASURING OCCURRENCE OF DISEASE
550
MEASURING RISK AND ASSOCIATION
551
TYPES OF EPIDEMIOLOGICAL STUDIES
553
THREATS TO VALIDITY AND RELIABILITY
556
MOVING FROM ASSOCIATION TO CAUSATION
558
CLINICAL EPIDEMIOLOGY
560
SEX, GENDER, RACE AND ETHNICITY IN EPIDEMIOLOGY
560
SUMMARY
561
ACKNOWLEDGMENTS
561
RECOMMENDED RESOURCES
561
REFERENCES
561
Chapter 36 Health Services Research: Translating Discovery and Research into Practice and Policy
564
WHAT IS HEALTH SERVICES RESEARCH AND WHAT ARE ITS GOALS?
564
ASSESSING MEDICAL INTERVENTIONS: OUTCOMES, EFFECTIVENESS AND COST-EFFECTIVENESS
565
MEDICAL DECISION MAKING
568
QUALITY MEDICAL CARE
573
CONCLUSIONS
581
REFERENCES
582
Part XI: Prospectus
584
Chapter 37 The Future of Clinical Research
586
DEFINITION OF TRANSLATIONAL HUMAN RESEARCH
586
SUBGROUPING OF BIOLOGICAL SCIENTISTS
587
THE PATIENT-ORIENTED SCIENTIST AT THE BEGINNING OF THE TWENTY-FIRST CENTURY
589
THE TWENTY-FIRST CENTURY AND THE FUTURE
590
REFERENCES
591
Index
592
A
592
B
592
C
592
D
594
E
594
F
595
G
595
H
596
I
596
J
597
K
597
L
597
M
597
N
597
O
598
P
598
Q
599
R
599
S
599
T
600
U
600
V
600
W
600
X
600
Alle Preise verstehen sich inklusive der gesetzlichen MwSt.